>

Receptor tyrosine kinase (monomer, inactive)

Q: Can I use the Receptor tyrosine kinase (monomer, inactive) icon in a BioRender figure or scientific illustration?

Yes — the Receptor tyrosine kinase (monomer, inactive) is fully integrated into BioRender's drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you're building from scratch or starting with a BioRender template.

Q: Can I export figures that include the Receptor tyrosine kinase (monomer, inactive) icon for publication or presentations?

Yes — figures containing the Receptor tyrosine kinase (monomer, inactive) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

Receptor tyrosine kinase (monomer, inactive) - Editable icon of A receptor tyrosine kinase monomer, with a large extracellular ligand binding domain and a transmembrane domain

[{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee77/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee77/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee76/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee76/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee75/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee75/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee74/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee74/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee73/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee73/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee72/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee72/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee71/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee71/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee70/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee70/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee6f/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee6f/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee6e/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee6e/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee6d/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee6d/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee6c/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee6c/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee6b/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee6b/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee6a/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee6a/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee69/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee69/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee68/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee68/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee67/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee67/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee66/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee66/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee65/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee65/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee64/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee64/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee63/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee63/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee62/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee62/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee61/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee61/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee60/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee60/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee5f/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee5f/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee5e/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee5e/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee5d/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee5d/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee5c/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee5c/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee5b/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee5b/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee5a/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee5a/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee59/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee59/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee58/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee58/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee57/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee57/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee56/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee56/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee55/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee55/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee54/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee54/5f6b62a10d0e450028a8ee52.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5f6b63460d0e450028a8ee53/5f6b62a10d0e450028a8ee52.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5f6b63460d0e450028a8ee53/5f6b62a10d0e450028a8ee52.png"}]

Keywords

keyword text

RTK,receptor tyrosine kinase,fgfr,vgfr,vegfr,ret,eph,ddr,monomer,inactive

BioRender icons and templates meet journal, grant, and copyright standards. For AI-generated figures, policies vary. Learn More

More Icons like this one in

Related Categories

Back To Library Home

Join 1,500,000 other scientists on BioRender

Sign up for your free account and start creating scientific figures faster today

Sign Up Free

FAQs

What is BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Receptor tyrosine kinase (monomer, inactive) icon along with our library of more than 30,000 life science icons.

Can I use this icon in a BioRender figure or scientific illustration?

Yes, the Receptor tyrosine kinase (monomer, inactive) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Receptor tyrosine kinase (monomer, inactive) icon customizable in BioRender?

Most icons in BioRender, including the Receptor tyrosine kinase (monomer, inactive) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

How are scientists using the Receptor tyrosine kinase (monomer, inactive) icon in their work?

BioRender users often use the Receptor tyrosine kinase (monomer, inactive) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Proteins.

Can I export figures that include the Receptor tyrosine kinase (monomer, inactive) icon for publication or presentations?

Yes, figures containing the Receptor tyrosine kinase (monomer, inactive) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

Is the Receptor tyrosine kinase (monomer, inactive) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Receptor tyrosine kinase (monomer, inactive) icon — especially those focused on Proteins. You can search BioRender’s template library or add this icon manually to any canvas.

Make scientific figures in minutes

Receptor tyrosine kinase (monomer, inactive)

Join 1,500,000 other scientists on BioRender

FAQs

Looking for science content?